Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin’s Therapeutic Potential in Chronic Kidney Disease
Life · 23.04.2026 · 16 (5) · 719
DOI: 10.3390/life16050719 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 23.04.2026. Verfasst von Aman Tedasen und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80161, Thailand. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a progressive global health challenge. While empagliflozin, a selective SGLT2 inhibitor, is known to attenuate CKD progression through mechanisms beyond glycemic control, the precise molecular pathways remain incompletely characterized and warrant further investigation. This study employed an integrated network pharmacology and molecular docking approach to elucidate the multi-target mechanisms of empagliflozin in CKD. Initial evaluation demonstrated that empagliflozin exhibits favorable physicochemical properties, drug-likeness, and ADMET profiles, supporting its potential as an effective orally administered therapeutic option for CKD management. Network analysis identified 221 shared molecular targets between empagliflozin and CKD-associated genes. Topological analysis of the protein–protein interaction (PPI) network revealed ten critical hub proteins—GAPDH, IL6, EGFR, HSP90AA1, NFKB1, HSP90AB1, MTOR, MAPK3, IL2, and PIK3CA—which serve as key regulators in CKD pathophysiology. Gene Ontology and KEGG pathway enrichment analyses indicated that these shared targets are significantly involved in phosphorylation, signal transduction, and central signaling cascades associated with CKD progression, including the PI3K-Akt, FoxO, HIF-1, and AGE-RAGE pathways. Molecular docking simulations corroborated empagliflozin’s multi-target affinity, demonstrating particularly strong binding energies toward HSP90AB1 (−10.85 kcal/mol), MAPK3 (−9.46 kcal/mol), and EGFR (−9.38 kcal/mol). Empagliflozin maintained stable hydrogen bonding throughout the 200-ns molecular dynamics simulation, primarily with GLN18, GLU42, SER45, ASN46, ASN101, GLY130, and TYR134, underscoring its persistent and well-anchored interaction with HSP90AB1. Collectively, these findings provide crucial mechanistic insights, suggesting that empagliflozin might exerts therapeutic effects by modulating interconnected pathways regulating inflammation, oxidative stress, and metabolic homeostasis, thereby reinforcing its role as a comprehensive, multi-target therapeutic strategy for CKD management. Nonetheless, validation through in vitro experiments remains necessary.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80161, Thailand.
- Research Excellence Center for Innovation and Health Products, Walailak University, Nakhon Si Thammarat 80161, Thailand.
- Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
- Nephrology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkhla University, Songkhla 90110, Thailand.
ORCID-Profile: Moragot Chatatikun, Ratana Netphakdee, Jason C Huang
Zitieren
APA
Tedasen, A., Chatatikun, M., Netphakdee, R., Huang, J. C., & Phongphithakchai, A. (2026). Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin’s Therapeutic Potential in Chronic Kidney Disease. Life, 16(5), 719. https://doi.org/10.3390/life16050719
Vancouver
Tedasen A, Chatatikun M, Netphakdee R, Huang JC, Phongphithakchai A. Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin’s Therapeutic Potential in Chronic Kidney Disease. Life. 2026;16(5):719. doi:10.3390/life16050719
BibTeX
@article{Tedasen2026,
author = {Tedasen, Aman and Chatatikun, Moragot and Netphakdee, Ratana and Huang, Jason C and Phongphithakchai, Atthaphong},
title = {Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin’s Therapeutic Potential in Chronic Kidney Disease},
journal = {Life},
year = {2026},
volume = {16},
number = {5},
pages = {719},
doi = {10.3390/life16050719}
}
EUVIMED